Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (20264)	5/8/1998 5:38:00 PM
From: RXGOLF	Read Replies (1) \| Respond to of 32384

Here is to next week!! Coverage InitiatedCompanySymbolBrokerage Firm¯ Initial Recommendation: ------------------------------------------------------------------------ Ligand PharmaLGNDLegg Mason¯ Buy Greg

To: Russian Bear who wrote (20264)	5/8/1998 10:45:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

RB, Legg Mason is just the beginning. They have a 12-18 month target of 20 and like LGND's partners.

To: Russian Bear who wrote (20264)	5/8/1998 11:13:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

RB, One poster on Yahoo expects quite a bit more: messages.yahoo.com@m2.yahoo.com I would be surprised by coverage by Vector, but would not be surprise by Merrill Lynch, Soloman Smith Barney, or UBS.

To: Russian Bear who wrote (20264)	5/9/1998 11:18:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

>Legg Mason -- 12-18 month target of 20. You're right, they don't read this thread (or is there a '0' missing?) :-)

To: Russian Bear who wrote (20264)	5/10/1998 9:54:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

RB, I have added the Legg Mason coverage to home.att.net under Legg Mason Analyst reports. I have also linked info on H&Q's prediction of $0.84 next year under the H&Q portion of the analysts' table.

To: Russian Bear who wrote (20264)	5/10/1998 10:12:00 AM
From: Henry Niman	Respond to of 32384

Here's the 3/27/98 H&Q Spot Report on LGND for those non-believers: Richard van den Broek Ligand Pharmaceuticals, Inc. LIGAND UPDATE BUY * Ligand announced yesterday positive results from its international Phase III trial for topical Panretin in patients with AIDS-related Kaposi's sarcoma (KS). The trial showed an overall response rate of 37.1% in the treatment arm compared with 6.9% in the placebo arm. * In order to include these data, Ligand plans to file a NDA for the topical agent in this indication by end of May, 6-8 weeks later than previously expected. * Separately, Ligand's partner Wyeth-Ayerst has filed an IND for a second generation tissue selective estrogen, TSE-424, for treatment of osteoporosis. * We reiterate our BUY rating. 2 '98 EPS -$ 0.51 Q1 Q2 Q3 Q4 FY '98 Revenues $ 58.7 '99 EPS $ 0.84 '99 Revenues $ 131.5 page Spot Report issued 3/27 @ 14:13 Recommendation: lgnd/$15.08/Notes: a, b,f/FY Ends Dec Biotechnology Estimates Revenue Estimates